Renvela Approval History
- FDA approved: Yes (First approved October 19th, 2007)
- Brand name: Renvela
- Generic name: sevelamer carbonate
- Dosage form: Tablets
- Company: Genzyme Corporation
- Treatment for: Hyperphosphatemia of Renal Failure
Renvela (sevelamer carbonate) is a calcium-free, metal-free, non-absorbed phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
Development History and FDA Approval Process for Renvela
|Oct 22, 2007||FDA Approves Genzyme's Renvela for Dialysis Patients|
|Dec 21, 2006||Genzyme Files for Approval of Sevelamer Carbonate for Patients on Dialysis|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.